Survival outcomes of east Asian patients with advanced non ‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence

ConclusionsThis real-world evidence shows that afatinib confers better survival than other first-line EGFR-TKIs in East Asian patients with advanced NSCLC.

Source: Thoracic Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Huang ‐Chih Chang, Kuo‐Tung Huang, Chia‐Cheng Tseng, Yu‐Mu Chen, Chien‐Hao Lai, Yu‐Ping Chang, Yung‐Che Chen, Hung‐Yi Chuang, Chin‐Chou Wang Tags: ORIGINAL ARTICLE Source Type: research